Hormone Axis Discussion
Hormone Axis Discussion Protocol
Educational protocol for hormone-signaling peptide discussions with clinicians
• This protocol is provided for educational and informational purposes only. It does not constitute medical advice, a diagnosis, a treatment plan, or a prescription.
• All dose ranges, frequencies, durations, and compound selections must be determined by a licensed healthcare professional based on your individual medical history, lab results, and clinical assessment.
• Lab monitoring may be required depending on the compound(s), individual health status, and duration of use. Discuss appropriate monitoring protocols with your clinician.
• Do not use any peptide compound if you are pregnant, breastfeeding, a minor, or have uncontrolled medical conditions without explicit direction from your physician.
High Risk — Specialist Supervision Required
Significant safety considerations; not suitable for unsupervised use
Overview
This HIGH RISK protocol covers discussion points for compounds that interact directly with the hypothalamic-pituitary-gonadal (HPG) axis or melanocortin receptor systems. These compounds require specialist endocrinology or reproductive medicine consultation.
Mechanism Summary
Hormone-axis compounds may modulate GnRH pulsatility, LH/FSH release, or central melanocortin signaling. They have significant downstream effects on reproductive hormones and require careful monitoring by specialist clinicians.
Intended Goal
Support informed clinician discussions on peptides affecting hormonal pathways
Kisspeptin-10
GnRH / reproductive axis
Studied for GnRH pulse regulation. Catalog reference only.
PT-141 (Bremelanotide)
Melanocortin / sexual function
FDA-approved for HSDD in premenopausal women; other uses require clinical evaluation.
Research reference values only. Confirm all parameters with current literature and your clinician.
Who may be a candidate
- ✓Adults under endocrinology care for hormonal conditions
- ✓Individuals with clinician-documented hypogonadism or reproductive concerns
- ✓Those prescribed PT-141 by a licensed physician for FDA-approved indications
Exclusions
- ✕Not appropriate for self-directed hormonal experimentation
- ✕Not suitable without endocrinology or reproductive medicine evaluation
- ✕Not for use in individuals with hormonally-sensitive conditions without specialist clearance
What does my full hormonal panel reveal?
Are there FDA-approved options for my indication I should consider first?
What are the cardiovascular risks given my health profile?
How frequently would you monitor my hormonal parameters?
Print or copy these questions using the "Copy Summary" button to bring to your appointment.
Legal & Compliance Notice
PT-141 (bremelanotide) has specific FDA-approved indications. Other hormonal compounds in this category are research-grade. Consult your clinician for jurisdiction-specific status.
The legal and regulatory status of research compounds varies by country and jurisdiction. It is the user's responsibility to understand applicable local laws before engaging with any compound.
This application does not provide personalized dosing recommendations. Users who require medical guidance should consult a qualified clinician.
Last reviewed: 2025-01-15 · Status: reviewed
Discuss with Your Clinician
Use this protocol as a research starting point. A qualified healthcare professional can review your health history, order appropriate labs, and help you determine what approach — if any — makes sense for your specific situation.